Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$0.99 USD

0.99
2,104,452

-0.01 (-1.00%)

Updated Jun 14, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BLUE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

bluebird bio, Inc. [BLUE]

Reports for Purchase

Showing records 441 - 460 ( 532 total )

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 441

05/21/2015

Daily Note

Pages: 5

As Expected, SCD Patient Treated with LentiGlobin on Track to Cure, Reiterate OUTPERFORM Rating and $222 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 442

05/21/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 443

05/21/2015

Daily Note

Pages: 5

As Expected, SCD Patient Treated with LentiGlobin on Track to Cure, Reiterate OUTPERFORM Rating and $222 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 444

05/21/2015

Company Report

Pages: 5

Preliminary SCD Data Suggests a Potential for a Functional Cure

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 445

05/19/2015

Company Report

Pages: 6

Earlier Launch Timing on Regulatory Update, Expect Additional Positive Newsflow with Release of EHA Abstracts this Week, Raising PT to $222

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 446

05/19/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 447

05/19/2015

Company Report

Pages: 8

Defined Path to Market, Target to $192

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 448

05/18/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 449

05/18/2015

Company Report

Pages: 9

EHA Abstract Preview

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 450

05/07/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 451

05/07/2015

Company Report

Pages: 9

Rapid Enrollment Points to Increasing Confidence on Safety Profile

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 452

05/06/2015

Company Report

Pages: 5

1Q15 Results, Awaiting Sickle Cell Data at EHAC, Abstracts Available May 21, Maintain OP rating

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 453

04/27/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 454

04/27/2015

Company Report

Pages: 8

SCD Data at ASH Makes The Most Clinical Sense

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 455

04/24/2015

Industry Report

Pages: 196

Healthcare - The State of Immunotherapy 3.0: "Silver Linings Immunobook"; Bright Horizons

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 150.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 456

04/23/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 457

04/22/2015

Daily Note

Pages: 6

Independent Validation and the Continued Resurgence in Gene Therapy

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 458

04/13/2015

Industry Report

Pages: 8

Biotechnology/Biopharmaceuticals: History Points to Limited Impact from Fed Rate Hikes and Heightened Volatility

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 459

04/10/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 13th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 460

04/07/2015

Industry Report

Pages: 2

Healthcare -Biotechnology: Catalyst Tracker Through Mid-15

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party